MEPRO-ASPIRIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mepro-aspirin, and what generic alternatives are available?
Mepro-aspirin is a drug marketed by Sandoz and is included in one NDA.
The generic ingredient in MEPRO-ASPIRIN is aspirin; meprobamate. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; meprobamate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MEPRO-ASPIRIN?
- What are the global sales for MEPRO-ASPIRIN?
- What is Average Wholesale Price for MEPRO-ASPIRIN?
Summary for MEPRO-ASPIRIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 36 |
| Clinical Trials: | 1,599 |
| DailyMed Link: | MEPRO-ASPIRIN at DailyMed |
Recent Clinical Trials for MEPRO-ASPIRIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Zunyi Medical College | Phase 4 |
| Assistance Publique Hopitaux De Marseille | N/A |
| North Eastern Indira Gandhi Regional Institute of Health ans Medical Sciences | Phase 3 |
US Patents and Regulatory Information for MEPRO-ASPIRIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz | MEPRO-ASPIRIN | aspirin; meprobamate | TABLET;ORAL | 089127-001 | Mar 2, 1987 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
